John Naim, PhD named WVCTSI director of operations on an interim basis

MORGANTOWN, W.Va. – John Naim, Ph.D. has been named interim director of operations for the West Virginia Clinical and Translational Science Institute, effective October 1, West Virginia Clinical and Translational Science Institute Director Sally Hodder, M.D., announced today (September 25).

Naim replaces Mary Huntley, M.P.H., who served in the role since August 2012 and is resigning to spend more time with family. Her last day with WVCTSI will be September 30.

Naim has led the Clinical Trials Research Unit at the West Virginia University Mary Babb Randolph Cancer Center since 2003, and he also currently leads the clinical trials arm of the West Virginia Clinical and Translational Science Institute. He began his career in research administration at Rochester General Hospital in Rochester New York before joining West Virginia University. He completed his Ph.D. in immunology at The State University of New York (SUNY) at Buffalo.

"Mary Huntley has worked tirelessly and enthusiastically to get the Institute off the ground and moving in the right direction, and I am grateful for her work and passion for WVCTSI. Dr. Naim has done a fabulous job leading the CTRU, and I am looking forward to working with him as his leadership role expands,” said Sally Hodder, MD, WVCTSI director.   Naim will continue his leadership of the Clinical Trials Research Units with the Mary Babb Randolph Cancer Center and WVCTSI throughout his interim appointment as director of operations.

sbc/9/25/14

CONTACT:

Stephanie Ballard Conrad,

West Virginia Clinical and Translational Science Institute

304.581.1843           wvctsi.org